Keeping Biologics in Suspension, Not Developers in Suspense: PK, Injectability and 18-Month Stability Data for Ultra-High-Concentration Subcutaneous Nanotrastuzumab

Session details:

High-dose biologics present major challenges for subcutaneous delivery, including concentration, injection volume, stability and injectability. Nanoform will share two key learnings from its nanotrastuzumab program: the potential of non-aqueous suspensions to enable small-volume, hyaluronidase-free delivery at ultra-high protein concentrations; and the critical role of particle engineering in creating stable, injectable formulations. New 18-month stability, injection-force and pharmacokinetic data highlight the potential of Nanoform’s platform to support the next generation of patient-centric subcutaneous biologics.